The purpose of this comprehensive forecast report presented by Fact.MR is to elaborate the various market projections impacting the global depression drugs market growth during the period through 2018-2026. This assessment delivers high-end statistics concerning market size, growth in trends and revenue share (US& Mn) linked to different geographies and segmentation types. Readers can acquire precise insights about market growth trends along with upcoming opportunities that are expected to reshape the overall structure of the depression drugs market during the forecast period.
Report Sample Request for Concerned Market - https://www.factmr.com/connectus/sample?flag=S&rep_id=3215
Depression comprises multiple mental health challenges characterized by the absence of positivity, which leads to feelings such as misery, sadness, and anxiety. Such feelings are normal only if they exist for a short period of time and it becomes a serious condition when the individual feels lost, angry, frustrated, and gloomy very frequently. Although prevalence of depression has gone up in the last decade, demand for depression drugs has witnessed a decline, as other forms of therapies, notably cognitive behavior therapy (CBT) has gained popularity. According to a study by the National Institute of Mental Health, over 10 Mn adults in the U.S. suffered from at least one depressive episode with severe results in 2016. The same study captured that the prevalence of depression is higher among female adults with 8.5% of cases as compared to 4.8% male adults.
Increase in the geriatric population and chronic diseases have been the crucial drivers for the growth of depression drugs market. With the rise in the health consciousness among the consumers, side-effects of the depression drugs are recognized and advanced technologies for the development of drugs with lesser side-effects are being used. However, the inclination of the consumers towards non-pharmacological therapies like CBT and meditation is likely to beset the growth of the global depression drugs market.
North America constitutes the largest share of the global depression drugs market, given the high concentration of established market players, which are focusing on enhancing the efficiency of these drugs. In addition, a rise in the awareness pertaining to the depression disorders created by mental healthcare organizations is expected to drive the growth of the market in this region. However, with increasing awareness pertaining to the health threats posed by the side-effects of the depression drugs, the consumers are gradually favoring non-clinical treatments over these drugs, which is anticipated to challenge the growth of the global market.
Following the trends of North America, Europe accounts for the second largest share of the depression drugs market, which can be attributed to the proliferated research and development activities to rethink the efficiency of depression drugs in this region.
Side Effects and Vulnerability to Addiction Create Reluctance among Patients
According to the study, depression drugs lose their efficacy after a few months or years since the brain becomes less responsive to such drugs. As a result, the normal brain functions begin to hamper. Symptoms such as blurred vision, vivid dreams, insomnia, fatigue, dizziness, and loss of coordination are observed by the patients who discontinue the intake of the drugs. These after-effects caused by these drugs are anticipated to limit the growth of the global depression drugs market.
Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=3215
According to the report, the significant players operating in the depression drugs market comprise of Johnson and Johnson, Sebela Pharmaceutical Inc., Takeda Pharmaceutical Company Ltd., GlaxoSmithKline, Novartis AG, Allergan USA Inc., AstraZeneca, Pfizer Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co., Ltd., Alkermes Plc, Bristol Myers Squibb Co., H. Lundbeck, and Teva Pharmaceutical Industries Ltd., among others. These leading players of the depression drugs market are adopting sustainable growth strategies to diversify their product portfolio, sustain their position in the global market, intensify their customer base, and garner share in the global depression drugs market.
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
11140 Rockville Pike
Suite 400, Rockville, MD 20852
Read Industry News at: https://insiderstribune.com
Depression Drugs Market Players Contribute Majorly towards Innovative Trends, details Fact.MR report
Contact Name: Basant
Contact Email: email@example.com
Contact Email: firstname.lastname@example.org